(Q35683216)

9 August 2017

1 reference

title

Benefit-risk assessment of tegaserod in irritable bowel syndrome (English)

1 reference

9 August 2017

main subject

irritable bowel syndrome

1 reference

Peter J Whorwell

2

0 references

author name string

Richard Lea

series ordinal

1

1 reference

9 August 2017

publication date

1 January 2004

1 reference

9 August 2017

1 reference

9 August 2017

volume

27

1 reference

9 August 2017

issue

4

1 reference

9 August 2017

page(s)

229-242

1 reference

Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects

9 August 2017

cites work

1 reference

12 December 2020

5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine

1 reference

12 December 2020

An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome

1 reference

12 December 2020

Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919).

1 reference

12 December 2020

Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome

1 reference

12 December 2020

AGA technical review on irritable bowel syndrome

1 reference

12 December 2020

A systematic review of tegaserod for the treatment of irritable bowel syndrome

1 reference

12 December 2020

Diagnosis of irritable bowel syndrome

1 reference

12 December 2020

Review article: tegaserod

1 reference

12 December 2020

Systematic review on the management of irritable bowel syndrome in North America.

1 reference

12 December 2020

The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat.

1 reference

12 December 2020

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

1 reference

12 December 2020

Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial

1 reference

12 December 2020

Design of treatment trials for functional gastrointestinal disorders

1 reference

12 December 2020

Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials

1 reference

12 December 2020

Characterization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle

1 reference

12 December 2020

Serotoninergic neuroenteric modulators

1 reference

12 December 2020

Tegaserod: a new 5-HT(4) agonist in the treatment of irritable bowel syndrome

1 reference

12 December 2020

U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation

1 reference

12 December 2020

Review article: the complexity of drug development for irritable bowel syndrome

1 reference

12 December 2020

Irritable bowel syndrome clinical trial design: future needs

1 reference

12 December 2020

Functional bowel disorders and functional abdominal pain

1 reference

12 December 2020

Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart

1 reference

12 December 2020

Serotonin: a mediator of the brain-gut connection

1 reference

12 December 2020

Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects

1 reference

12 December 2020

Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms

1 reference

12 December 2020

Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum

1 reference

12 December 2020

Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications

1 reference

12 December 2020

Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization

1 reference

12 December 2020

Partial agonists and G protein-coupled receptor desensitization

1 reference

12 December 2020

Controlled treatment trials in the irritable bowel syndrome: a critique.

1 reference

12 December 2020

Irritable bowel syndrome in office-based practice in the United States

1 reference

12 December 2020

Serotonin transporter gene polymorphism in irritable bowel syndrome

1 reference

12 December 2020

Tegaserod coadministration does not alter the pharmacokinetics of theophylline in healthy subjects

1 reference

12 December 2020

Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity

1 reference

12 December 2020

Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome

1 reference

12 December 2020

Quality of life in irritable bowel syndrome

1 reference

12 December 2020

Irritable bowel syndrome symptom patterns: frequency, duration, and severity

1 reference

12 December 2020

Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome

1 reference

12 December 2020

The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects

1 reference

12 December 2020

Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome

1 reference

12 December 2020

Towards positive diagnosis of the irritable bowel

1 reference

12 December 2020

In vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: a segmental perfusion study

1 reference

12 December 2020

Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers

1 reference

12 December 2020

5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle

1 reference

12 December 2020

Abdominal and pelvic surgery in patients with irritable bowel syndrome

1 reference

12 December 2020

What the gastroenterologist does all day. A survey of a state society's practice

1 reference

12 December 2020

10.2165/00002018-200427040-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

9 August 2017

1001362266

0 references

1 reference